RET Fusions in NSCLC
The RET (rearranged during transfection) is a novel fusion gene with various partners including KIF5B (kinesin family member 5B) and others such as CCDC6, NCOA4, and TRIM33. It is found in around 1–2% of lung adenocarcinomas and predominantly in non-smokers. No specific RET inhibitors are currently available but multi-kinase inhibitors such as vandetanib (phase II) and cabozantinib (phase III) are being trialled in RET fusion-positive NSCLC (ClinicalTrials.gov Identifiers: NCT01823068 and NCT01639508).